# Phase II trial of olaparib in patients with advanced castration resistant prostate cancer

Submission date 19/07/2012	<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li></ul>		
		☐ Protocol		
Registration date 19/07/2012	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
27/11/2025	Cancer			

#### Plain English summary of protocol

http://cancerhelp.cancerresearchuk.org/trials/a-trial-of-olaparib-for-prostate-cancer-that-has-spread-and-got-worse-despite-hormone-therapy-and-chemotherapy-toparp

## Contact information

## Type(s)

Scientific

#### Contact name

Ms Claire Paulding

#### Contact details

ICR Clinical Trials & Statistics Unit (ICR-CTSU) Section of Clinical Trials, Sir Richard Doll Building 15 Cotswold Road Sutton United Kingdom SM2 5NG

Toparp-icrctsu@icr.ac.uk

## Additional identifiers

Clinical Trials Information System (CTIS)

2011-000601-49

ClinicalTrials.gov (NCT)

NCT01682772

Protocol serial number

# Study information

#### Scientific Title

TOPARP: Phase II Trial of Olaparib in Patients with Advanced castration Resistant Prostate cancer: a non-randomised study

#### Acronym

**TOPARP** 

#### **Study objectives**

Prostate cancer is the second commonest cause of male cancer death in the UK with a third of patients developing advanced disease. This initially responds to treatment called androgen deprivation, but invariably progresses to a terminal phase, called castration resistant. Docetaxel is the mainstay of treatment for patients with metastatic castration resistant prostate cancer (mCRPC) but only 40-45% of patients have a survival benefit from this treatment. Thus, effective therapeutic options that offer sustained responses and clinical benefit for mCRPC patients remain an important area of unmet medical need. Prostate cancer is a clinically and molecularly heterogeneous disease. Improved understanding of the biological and clinical significance of the molecular subclassification of this disease could positively impact treatment outcomes by allowing doctors to target the most appropriate therapy for patients.

We hypothesise that a proportion of mCRPC have defects in a form of DNA repair. The drug olaparib has shown activity in other cancer types that have this DNA repair deficit and we are testing whether mCRPC patients also will benefit from olaparib treatment. We also hope that predictive biomarkers can be identified to define this patient population.

The aims and objectives of this trial are therefore:

- 1. To evaluate the antitumour activity of olaparib in mCRPC.
- 2. To identify predictive biomarkers of HR repair deficiency for mCRPC. To do this, we have developed a novel trial designed to test the benefit of the drug while looking for molecular predictors of clinical response.

More details can be found at http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=12313

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

NRES Committee London - Surrey Borders, 29/12/2011, ref: 11/LO/2019

## Study design

Non-randomized; Interventional; Design type: Treatment

## Primary study design

Interventional

## Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Prostate Cancer; Disease: Prostate

#### **Interventions**

All patients will receive single agent olaparib (AZD2281) at a dose of 400 mg twice daily, continuously on a 28-day cycle. Olaparib will be administered until objective disease progression or unacceptable toxicity or patient withdrawal for whatever reason.

#### Added 27/11/2025:

Additional Data Linkage Information:

Participants from this trial will also be included in the INTERACT project which will link to their data held by NHS England. For more information, please see the INTERACT website: https://www.icr.ac.uk/interact.

#### Intervention Type

Drug

#### Phase

Phase II

#### Drug/device/biological/vaccine name(s)

Olaparib

#### Primary outcome(s)

Response will be defined on the basis of the following outcomes, if any of these occur patients will be considered to have responded:

- 1. Objective response by modified Response Evaluation Criteria In Solid Tumors (RECIST)
- 2. Prostate-specific antigen (PSA) decline of ≥50% according to the Prostate Cancer Working Group 2 and
- 3. Conversion of circulating tumour cell count (CTC) from ≥5 cells/7.5ml blood at baseline to <5 cells/7.5ml blood confirmed by at least 2 readings 4 weeks apart

## Key secondary outcome(s))

- 1. Radiological progression free survival
- 2. Time to radiological progression
- 3. Progression free survival
- 4. Overall survival
- 5. Time to PSA progression
- 6. Proportion of patients with conversion of circulating tumour cell count from ≥5 cells/7.5ml blood at baseline to <5/7.5ml blood nadir
- 7. Duration of PSA response and objective response if applicable
- 8. Safety and tolerability of Olaparib

#### Completion date

31/01/2014

# Eligibility

## Key inclusion criteria

- 1. The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document
- 2. Age >= 18 years
- 3. Histologically confirmed adenocarcinoma of the prostate with tumour tissue available for molecular analyses. If archival tissue for biomarker analysis is not available then the patient must be willing to have a further biopsy to obtain tumour tissue for histological diagnosis.
- 4. At least one but no more than two previous taxanebased chemotherapy regimens. If docetaxel chemotherapy is used more than once, this will be considered as one regime. Patients may have had prior exposure to cabazitaxel treatment.
- 5. At least 28 days since the completion of prior therapy, including major surgery, chemotherapy and other investigational agents. Additionally, clinically relevant sequelae should have resolved to grade 1 or less prior to recommencing treatment. For hormonal treatment and radiotherapy refer to the guidelines below:
- 5.1. At least 28 days since the completion of prior flutamide treatment. Patients whose Prostate-specific antigen (PSA) did not decline in response to anti-androgens given as a second line or later intervention will only require a 14 days washout prior to Cycle 1, Day 1.
- 5.2. At least 42 days since the completion of prior bicalutamide (Casodex) and nilutimide (Nilandron) treatment. Patients whose PSA did not decline for 3 or 4 months in response to antiandrogens given as second line or later intervention will require only a 14 day washout period prior to Cycle 1 Day1.
- 5.3. At least 14 days from any radiotherapy with the exception of a single fraction of radiotherapy for the purposes of palliation (confined to one field) is permitted.
- 6. Documented prostate cancer progression as assessed by the investigator with one of the following:
- 6.1. PSA progression defined by a minimum of three rising PSA levels with an interval of >= 1 week between each determination. The PSA value at the Screening visit should be  $>= 2 \mu g/L$  (2 ng /ml); patients on systemic glucorticoids for control of symptoms must have documented PSA progression by PCWG22 while on systemic glucocorticoids prior to commencing Cycle1 Day1 of treatment.
- 6.2. Radiographic progression of soft tissue disease by modified RECIST criteria or of bone metastasis with two or more documented new bone lesions on a bone scan with or without PSA progression.
- 7. Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM). If the patient is being treated with LHRH agonists (patient who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study.
- 8. Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 2 (Karnofsky Performance Status = 50%)
- 9. Life expectancy > 12 weeks
- 10. Patient must be able to swallow a whole tablet
- 11. Patient and the patients partner of childbearing potential, must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 3 months after the last dose of study drug.
- 12. Agreeable to have all the biomarker studies including the paired fresh tumour biopsies
- 13. Subjects must have a circulating tumour cell (CTC) count of  $\geq$  5 cells/7.5mls blood at screening
- 14. Subjects must have adequate bone marrow, hepatic and renal function documented within 7 days of registration, defined as:
- 14.1. Haemoglobin >=10g/dL independent of transfusions
- 14.2. White blood cells >3x109/L
- 14.3. Absolute neutrophil count >=1.5x109/L

- 14.4. Platelets >=100 x109/L
- 14.5. Total bilirubin <= 1.5 x upper limit of normal (ULN) except for patients with known Gilberts syndrome.
- 14.6. Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT)  $\leq$  2.5 x ULN or  $\leq$  5 x ULN in the presence of liver metastases
- 14.7. Serum creatinine <=1.5 x ULN or a calculated creatinine clearance >40mL/min for patients with creatinine levels above institutional normal. For GFR estimation, the Cockcroft and Gault equation should be used: GFR = CrCl (ml/min) =  $(140 \text{ age}) \times \text{wt (kg)/(serum creatinine} \times 72)$  14.8. Albumin >30 g/dl

#### Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

Mixed

#### Lower age limit

18 years

#### Upper age limit

100 years

#### Sex

Male

#### Total final enrolment

0

#### Key exclusion criteria

- 1. Surgery, or local prostatic intervention (excluding a prostatic biopsy) less than 28 days of Cycle 1 Day 1
- 2. Less than 28 days from any active anticancer therapy or investigational agents. For hormonal treatment and radiotherapy refer to the guidelines outlined in the inclusion criteria
- 3. Prior treatment with a PARP inhibitor, platinum, cyclophosphamide or mitoxantrone chemotherapy
- 4. Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart disease), unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements
- 5. Any acute toxicities due to prior chemotherapy and / or radiotherapy that have not resolved to a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4. 02 grade 1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy. 6. Malignancy within the previous 2 years with a > 30% probability of recurrence within 12 months with the exception of non-melanoma skin cancer, in-situ or superficial bladder cancer
- 7. Patients with myelodysplastic syndrome/acute myeloid leukaemia
- 8. Patients with known symptomatic brain metastasis are not suitable for enrolment. Patients

with asymptomatic, stable, treated brain metastases are eligible for study entry

- 9. Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable and asymptomatic
- 10. Patients who experience a seizures within 6 months of study treatment or who are currently being treated with cytochrome P450 enzyme inducing antiepileptic drugs for seizures (use of antiepileptic drugs to control pain is allowed in patients not suffering from seizures unless drug is excluded due to CYP3A4 induction phenytoin, carbamazepine, phenobarbital
- 11. Patients receiving any of the following classes of inhibitors of CYP3A4; -Azole antifungals Macrolide antibiotics -Protease inhibitors 12. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication
- 13. Initiating bisphosphonate therapy or adjusting bisphosphonate dose/regimen within 30 days prior to Cycle 1 Day 1. Patients on a stable bisphosphonate regimen are eligible and may continue.
- 14. Presence of a condition or situation, which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
- 15. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee

Date of first enrolment 04/07/2012

Date of final enrolment 31/01/2014

## Locations

**Countries of recruitment**United Kingdom

England

Study participating centre ICR Clinical Trials & Statistics Unit (ICR-CTSU)

Sutton England SM2 5NG

# Sponsor information

#### Organisation

The Institute for Cancer Research (UK)

#### Organisation

Royal Marsden Hospital NHS Foundation Trust (UK)

#### Organisation

Institute of Cancer Research

#### **ROR**

https://ror.org/043jzw605

# Funder(s)

### Funder type

Industry

#### **Funder Name**

AstraZeneca

#### Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics, AZ

## **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

For-profit companies (industry)

#### Location

**United Kingdom** 

#### **Funder Name**

Cancer Research UK (UK)

#### Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Other non-profit organizations

#### Location

**United Kingdom** 

# **Results and Publications**

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not expected to be made available

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	29/10/2015		Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes